Trillium Therapeutics (TR) Reaches New 52-Week Low at $1.52

Share on StockTwits

Shares of Trillium Therapeutics Inc (TSE:TR) (NASDAQ:TRIL) hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$1.52 and last traded at C$0.00, with a volume of 49075 shares traded. The stock had previously closed at C$29.80.

Trillium Therapeutics (TSE:TR) (NASDAQ:TRIL) last released its earnings results on Wednesday, November 14th. The company reported C($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of C($0.87) by C($0.04).

ILLEGAL ACTIVITY WARNING: “Trillium Therapeutics (TR) Reaches New 52-Week Low at $1.52” was first posted by Macon Daily and is the property of of Macon Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://macondaily.com/2019/02/11/trillium-therapeutics-tr-reaches-new-52-week-low-at-1-52.html.

About Trillium Therapeutics (TSE:TR)

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1).

Featured Story: How to Invest in an Index Fund

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply